Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $23.32M
• Dividend Yield: N/A
• Average Volume (3M): 908.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 29,241,741
• 10 Day Avg. Volume: 2,157,193
• 30 Day Avg. Volume: 908,398
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 0.44
• Enterprise Value/Gross Profit: 4.74
• Enterprise Value/Ebitda: -1.90
• 1Y Price Target: $1.00
• Price Target Upside: 25.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: $1.00 ▲(25.00% Upside)

Cosmos Holdings' overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. While technical analysis indicates some positive momentum, the poor valuation metrics due to negative earnings and lack of dividends weigh heavily on the score. Improvement in financial health is crucial for a better outlook.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Cosmos Holdings makes money primarily through the sale of its pharmaceutical and nutraceutical products. The company's revenue streams include direct sales to healthcare providers, pharmacies, and hospitals, as well as partnerships with other pharmaceutical companies for the distribution of their products. Revenue is also generated through the company's proprietary brands and products, which are marketed and sold in various international markets. Strategic partnerships and distribution agreements play a significant role in expanding the company's reach and enhancing its earnings potential.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings faces significant financial hurdles with persistent net losses, shrinking revenue, and negative cash flows. While there are signs of reducing debt, the company's financial health remains strained by operational inefficiencies and a heavy reliance on liabilities.

Income Statement

Cosmos Holdings' income statement reveals challenges in profitability, with consistent net losses and negative EBIT and EBITDA margins over recent periods. The TTM data shows a slight reduction in revenue, indicating a -1.60% revenue growth rate compared to the previous annual period. Despite some improvement in gross profit margin over the TTM period, the negative net profit margin and declining revenue indicate struggles in operational efficiency and market position.

Balance Sheet

The balance sheet of Cosmos Holdings shows moderate financial stability with a debt-to-equity ratio stabilizing as stockholders' equity increases. However, high total liabilities and low equity ratios reflect potential solvency concerns. The company has reduced total debt significantly over the TTM period, but the equity ratio remains weak, indicating a heavy reliance on liabilities.

Cash Flow

Cosmos Holdings' cash flow statement highlights ongoing liquidity challenges, with negative free cash flow and operating cash flow over recent periods. The TTM shows a negative free cash flow growth rate of approximately 30.05% compared to the previous year, indicating inefficiencies in cash generation. The operating cash flow to net income ratio remains negative, underscoring persistent cash burn issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	336.25K	3.85M	20.76M	293.18K	851.19K
Total Debt	11.82M	12.42M	12.03M	27.12M	32.04M
Total Liabilities	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Positive. The current price of 0.8 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.55, and above the 200-day MA of 0.58, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 54.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	65 Neutral	$14.62M	―	3.29%	―	-26.17%	―
COSM	52 Neutral	$23.32M	―	-58.30%	―	―	―
Sector *	51 Neutral	$7.38B	-0.04	-62.85%	2.34%	15.18%	-2.87%
BFRI	49 Neutral	$10.34M	―	-384.98%	―	14.27%	87.31%
TXMD	47 Neutral	$12.28M	―	-7.72%	―	35.25%	81.05%
FLGC	39 Underperform	$10.86M	―	-230.73%	―	-24.10%	38.17%